Back to FundingFunding

Talkiatry Closes $210M Series D to Scale AI-Powered Psychiatry

The telepsychiatry platform raised $210M to expand its AI copilot for clinicians and scale psychiatric care delivery. Talkiatry now serves over 1 million patients across 50 states.

Body Mind StateFebruary 10, 20264 min read
Talkiatry Closes $210M Series D to Scale AI-Powered Psychiatry

$210 Million to Scale Mental Health Infrastructure

Talkiatry has raised $210 million in a Series D round, making it one of the best-funded mental health platforms in the country. The company combines telepsychiatry with AI-powered clinical tools to deliver psychiatric care at scale.

What Makes Talkiatry Different

Unlike consumer wellness apps, Talkiatry operates as a full-service psychiatric practice:

  • Licensed psychiatrists prescribe and manage medication
  • AI copilot handles clinical documentation, reducing administrative burden by 40%
  • Insurance-first model — accepts most major insurance plans
  • Measurement-based care — tracks patient outcomes using validated scales

The AI Component

Talkiatry's AI system acts as a clinical copilot that:

  • Generates session notes from audio transcription
  • Flags potential drug interactions and contraindications
  • Suggests evidence-based treatment adjustments based on outcome data
  • Reduces clinician burnout by automating the documentation burden

Why This Matters

The U.S. faces a severe shortage of psychiatrists — fewer than 30,000 practicing psychiatrists serve a population of 330 million. Talkiatry's model addresses this by maximizing the clinical capacity of each provider through AI-assisted workflow.

The Investment Signal

This round reflects a broader trend: investors are moving capital away from consumer wellness apps toward clinical infrastructure. The companies winning funding in 2026 are those with real clinicians, real insurance contracts, and real patient outcomes.

Original Publication
Company Website
Read Source →

Related

Stay Regulated

Regulate your nervous system from the inside out.

New research, honest product reviews, clinical trials, events, and funding news — delivered weekly, with zero sponsors or ads.